HIV immunoassays using synthetic envelope polypeptides

Details HIV immunoassays using synthetic envelope polypeptides HIV immunoassays using synthetic envelope polypeptides

2007-09-25

2007-09-25

Zeman, Mary K. (Department: 1631)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S007100, C435S069100, C435S320100, C435S069300, C435S974000, C436S501000, C424S188100, C424S204100, C424S208100

Reexamination Certificate

active

08089407

ABSTRACT:
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

REFERENCES:
patent: 4520113 (1985-05-01), Gallo
patent: 4629783 (1986-12-01), Cosand
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 4716102 (1987-12-01), Levy
patent: 4774175 (1988-09-01), Chang et al.
patent: 5156949 (1992-10-01), Luciw et al.
patent: 35 87 394 (1993-06-01), None
patent: 0 020 251 (1980-12-01), None
patent: 0 060 057 (1982-09-01), None
patent: 0 062 574 (1982-10-01), None
patent: 0 073 635 (1983-03-01), None
patent: 0 088 632 (1983-09-01), None
patent: 0 116 201 (1984-08-01), None
patent: 0 136 798 (1985-04-01), None
patent: 0 138 667 (1985-04-01), None
patent: 0 139 216 (1985-05-01), None
patent: 0 152 030 (1985-08-01), None
patent: 0 165 120 (1985-12-01), None
patent: 0 173 529 (1986-03-01), None
patent: 0 178 978 (1986-04-01), None
patent: 0 181 150 (1986-05-01), None
patent: 0 181 150 (1986-05-01), None
patent: 0 185 444 (1986-06-01), None
patent: 0 187 041 (1986-07-01), None
patent: 0 201 540 (1986-11-01), None
patent: 0 178 978 (1992-02-01), None
patent: 2104902 (1983-03-01), None
patent: 84/23659 (1984-09-01), None
patent: 84/16013 (1984-10-01), None
patent: 84/29099 (1984-11-01), None
patent: 85/01473 (1985-01-01), None
patent: 85/04897 (1985-11-01), None
patent: 85/04903 (1985-11-01), None
patent: 86/02383 (1986-04-01), None
patent: 86/06414 (1986-11-01), None
Barre-Sinoussi et al., Science 220:868-871(1983).
Geysen et al., “Use of Peptide Synthesis to Probe . . . ,” Proc Natl Acad Sci (USA) 81:3998-4002.
Arya et al., “Homology of genome of AIDS-associated virus with genomes of human T-cell leukemia virsuses,” SCIENCE, (Aug. 31, 1984) 225 (4665) 927-30.
Altman et al., “Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2,” Proc Natl Acad Sci (USA), (Apr. 1984) 81 (7) 2176-80.
Barkas et al., “Antibodies to synthetic peptides as probes of acetylcholine receptor structure,” European Journal of Biochemistry, (Sep. 3, 1984) 143 (2) 309-14.
Bellet et al., “A monoclonal antibody against a synthetic peptide is a specific for the free native human chorionic gonadotropin beta-subunit,” Endocrinology, (Jul. 1984) 115 (1) 330-6.
Broliden et al., “Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins,” Proc Natl Acad Sci (USA), (Jan. 15, 1992) 89 (2) 461-5.
Dale et al., “Type-specific immunogenicity of chemcially synthesized fragment of type 5 streptococcal M protein,” Journal of Experimental Medicine, (Nov. 1, 1983) 158 (5) 1727-32.
Gallo et al., “Isolation of human T-cell leukemia virus in acquired immune dificiency syndrome (AIDS),” SCIENCE, (May 20, 1983) 220 (4599) 865-7.
Goudsmit et al., “Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe,” INTERVIROLOGY, (1990) 31 (6) 327-38.
Green et al., “Human adenovirus 2 E1B-19K and E1B-53K tumor antigens: antipeptide antibodies targeted to the NH2 and COOH termini,” Journal of Virology, (Dec. 1983) 48 (3) 604-15.
Hintz et al., “Characterization of an insulin-like growth factor-I/somatomedin-C radioimmunoassay specific for the C-peptide region,” Journal of Clinical Endocrinology and Metabolism, (Nov. 1982) 55 (5) 927-30.
Hirayama et al., “Structural relationships between carrier epitopes and antigenic epitopes on hen egg-white lysozyme,” Immunology, (May 1982) 46 (1) 145-54.
Hopp T P; Woods K R, “Prediction of protein antigenic determinants from amino acid sequences,” Proc Natl Acad Sci (USA), (Jun. 1981) 78 (6) 3824-8.
Hopp T P; Woods K R, “A computer program for predicting protein antigenic determinants,” Molecular Immunology, (Apr. 1983) 20 (4) 483-9.
Jacob et al., “Antibodies against synthetic peptides fo the B subunit of cholera toxin: crossreaction and neutralization of the toxin,” Proc Natl Acad Sci (USA), (Dec. 1983) 80 (24) 7611-5.
Jiang et al., “Specific anitbody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection,” Journal of Aquired Immune Deficiency Syndromes, (1992) 5 (4) 382-90.
Jolivet et al., “Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant,” Biochemical and Biophysical Research Communications, (Dec. 16, 1983) 117 (2) 359-66.
Kennedy et al., “Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein,” SCIENCE, (Mar. 28, 1986) 231 (4745) 1556-9.
Kennedy et al., “Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope,” Journal of Biological Chemistry, (Apr. 25, 1987) 262 (12) 5769-74.
Krowka et al., “Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individuals,” Clinical Immunology and Immunopathology, (Apr. 1991) 59 (1) 53-64.
Lando et al., “Antigenic structure of sperm whale myoglobin. II. Characterization of antibodies preferentially reactive with peptides arising in response to immunization with the native protein,” Journal of Immunology, (Jul. 1982) 129 (1) 212-6.
Leach S J, “How antigenic are antigenic peptides?,” Biopolymers, (Jan. 1983) 22 (1) 425-40.
Lieu et al., “Multiple antigenic sites on an eicosapeptide. I. Precipitin studies in the goat,” IMMUNOLOGY, (Dec. 1975) 29 (6) 1133-43.
Meshcheryakova et al., “CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments,” Molecular Immunology, (Aug. 1993) 30 (11) 993-1001.
Montagnier et al., “Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines,” SCIENCE, (Jul. 6, 1984) 225 (4657) 63-6.
Morrow et al., “The antibody response to a single antigenic determinant of the tobacco mosaic virus protein: analysis using monoclonal antibodies, mutant proteins and synthetic peptides,” Molecular Immunology, (Apr. 1984) 21 (4) 301-9.
Morrow et al., “The antibody response to a single antigenic determinant of the tobacco mosaic virus protein (TMVP): effects of allotype-linked genes and restricted heterogeneity of the response,” Journal of Immunology, (Dec. 1983) 131 (6) 2875-81.
Muller et al., “Localization of two antigenic determinants in histone H4,” Biochimica et Biophysica Acta, (Sep. 14, 1983) 747 (1-2) 100-6.
Pacella et al., “Induction of fibrin-specific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites,” Molecular Immunology, (May 1983) 20 (5) 521-7.
Palker et al., “A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope,” Proc Natl Acad Sci (USA), (Apr. 1987) 84 (8) 2479-83.
Pauletti et al., “Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein,” Analytical Biochemistry, (Dec. 1985) 151 (2) 540-6.
Popovic et al., “Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patien

Affiliated with

Also associated with

Rating

HIV immunoassays using synthetic envelope polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV immunoassays using synthetic envelope polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV immunoassays using synthetic envelope polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3736159